Physician profile
Robert Aden
NPI 1457312829
$7,903.06
in general payments reported to CMS, 2019-2025
26 companies · $654 in 2025
The $654 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,646 · 2020: $40.93 · 2021: $472 · 2022: $1,024 · 2023: $267 · 2024: $799 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,719.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $4,733.99 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $477.99 | 2021-2024 | Jardiance, Tradjenta |
| Lilly USA, LLC | $454.23 | 2021-2025 | Zepbound, Jardiance, Mounjaro |
| Medtronic, INC. | $400.13 | 2021-2025 | Minimed 780g, Minimed 770g |
| Amarin Pharma, INC. | $345.16 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $218.73 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $184.45 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Amneal Pharmaceuticals LLC | $126.92 | 2021-2025 | Unithroid |
| Abbott Laboratories | $117.52 | 2021-2022 | |
| Cequr Corporation | $112.80 | 2022-2024 | Cequr Simplicity |
| Tandem Diabetes Care, INC. | $102.12 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $99.28 | 2024-2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $69.12 | 2024 | |
| Insulet Corporation | $60.59 | 2019-2025 | Omnipod |
| Astrazeneca Pharmaceuticals Lp | $52.46 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $46.51 | 2025 | Yorvipath |
| Corcept Therapeutics | $41.19 | 2024 | Korlym |
| Ibsa Pharma INC. | $40.87 | 2022 | |
| Beta Bionics, INC. | $40.30 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Vifor Pharma, INC. | $37.03 | 2025 | Veltassa |
| Merck Sharp & Dohme LLC | $36.33 | 2019 | |
| Abbvie INC. | $32.15 | 2022 | |
| Boston Scientific Corporation | $20.66 | 2022 | |
| Antares Pharma, INC. | $20.37 | 2024 | Xyosted |
| Dexcom, INC. | $18.16 | 2022 | |
| Currax Pharmaceuticals LLC | $14.00 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Aden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.